Paul Berg Quotes

I think that in the 21st century, medical biology will advance at a more rapid pace than before.

I'd like to focus on my life on creating new medicines for people who are suffering from rare disease.

The United States has an active pharmaceutical industry that has brought huge benefits to the U.S. public. Most Americans, who benefit from these advances, have little understanding of how difficult it is to create an important new medical therapy and make it available to improve public health.

Affordability is critical so that patients have access to medicines. At the same time, it's also important that we have the kind of incentives that allow us to do the kinds of studies that we need to do to go after these diseases like Alzheimer's.

We'll be investing in basic science research with the goal of curing disease.

To ensure that America remains the leader in medical innovation, we must reduce the costs of developing life-saving drugs and ensure that there are appropriate economic incentives in place to produce them.

Biotech research is incredibly important for health-care innovation.

On the third stage is used for medicine, it is not known to the public.

Scientists have established huge numbers of links between particular diseases and snippets of DNA, but in the great majority of cases, this has not yet been translated into treatments that can help cure patients. These treatments will come - tomorrow, or the day after.

I agree, the world would be a better place if doctors were less enthusiastic about adopting very new drugs.

Now, what tends to happen is that the stories get hyped. And the medicines are not quite as revolutionary and as dramatic as they seem to be. But, certainly, various phases of this problem are being attacked by the pharmaceutical companies.

I keep encouraging the pharmaceutical companies to put more money into R&D.

New drugs and surgical techniques offer promise in the fight against cancer, Alzheimer's, tuberculosis, AIDS, and a host of other life-threatening diseases. Animal research has been, and continues to be, fundamental to advancements in medicine.

One of the things that launched the strength in biotech is when the pharmaceutical industry itself got a little slow.

St. Louis has always been a great center for medicine. It has been a leader in the nation since the early part of the 20th century. Along with that, we've been a leader in medical science and biomedical science and innovation in medicine.

We now have the ability to explore many new treatments for many diseases. However we do not have enough money to explore them all…. I measure time by the number of patients who die each day as the result of diseases that we do not have enough money to develop cures for. We have the tools. We need the money.

Biopharmaceutical research and development efforts have achieved dramatic improvements in global health and longevity, and we are committed to continuing our quest.

Gene therapies and other treatments that can cure - not just treat - disease are going to be expensive. All of the cost of innovating and reaping an economic return may need to be recouped in a single payment.

It seems paradoxical that, as medical scientists make huge advances in discovering the mechanisms of common diseases, fewer and fewer innovative drugs are reaching the market.

While I am prepared to look at all options and to think 'outside the box' for effective treatments, I rightly resisted efforts to provide an unproven drug on demand to the American public.

In contrast to how tech firms want to disrupt and break things - developing drugs must be incremental and step-by-step. This is the kind of work that involves people putting their lives on the line every day with clinical trials.

To start with, pharma was an industry based on innovation, drug discovery.

My job is to stay alive until the medicine and research catch up.

One problem I have with drug companies is that they don't make all their data public.

I believe that life-saving, essential drugs should be freely available and the innovator should be paid a suitable royalty payment for his invention.